Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

NCT01159249 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Vildagliptin

Sponsor

Novartis Pharmaceuticals